Arcutis Biotherapeutics, Inc. cash flow to debt ratio of -89.77% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Arcutis Biotherapeutics, Inc.'s free cash flow has increased -94.38% from $-112.30M last year to $-6.31M, signaling increasing performance

Arcutis Biotherapeutics, Inc.'s debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Arcutis Biotherapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.70 last year to 0.07 today, signaling strengthened financials

Arcutis Biotherapeutics, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Arcutis Biotherapeutics, Inc.'s interest coverage ratio is 0.24, which means that the company struggles to meet interest obligations, signaling financial risk.

Arcutis Biotherapeutics, Inc.'s profit margin has increased (-99.20%) in the last year from -71.25% to -0.57%, signaling increasing performance

Arcutis Biotherapeutics, Inc.'s short-term assets of $411.23M exceed its short-term liabilities of $129.84M

Arcutis Biotherapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Arcutis Biotherapeutics, Inc.'s return on equity of -1.41%, is lower than 15.00%, indicating bad performance

Arcutis Biotherapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Arcutis Biotherapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Arcutis Biotherapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Arcutis Biotherapeutics, Inc. has negative free cash flow, indicating cash burn

Arcutis Biotherapeutics, Inc.'s yearly earnings has increased -88.47% since last year from $-140.04M to $-16.14M, signaling increasing performance

Arcutis Biotherapeutics, Inc.'s yearly revenue has increased 91.34% since last year from $196.54M to $376.07M, signaling increasing performance

ROIC 1.05% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Arcutis Biotherapeutics, Inc.'s 3-year revenue CAGR of 367.27% is positive, indicating growing revenue over the past 3 years

Arcutis Biotherapeutics, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Arcutis Biotherapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Arcutis Biotherapeutics, Inc. has insufficient data to evaluate this check.

Arcutis Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arcutis Biotherapeutics, Inc. is overvalued relative to its fair value price of 0.44 based on EBITDA multiple model

Arcutis Biotherapeutics, Inc. has an EV/EBITDA ratio of 223.30x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Arcutis Biotherapeutics, Inc. has insufficient data to evaluate this check.

Arcutis Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arcutis Biotherapeutics, Inc. has a price-to-book ratio of 18.42x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Arcutis Biotherapeutics, Inc. has a price-to-sales ratio of 8.13x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue